MedTrace Logo

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

NCT02885324 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-10-06

Study results available
· View outcomes & findings →

Summary

This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory central nervous system tumors for which there are no curative options. Patients will also be followed for safety, time to progression, event free survival and overall survival

Conditions

Interventions

DRUG

Cabozantinib

Subjects will receive Cabozantinib

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Scott Coven, DO · Indiana University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-18
Primary Completion
2020-08-25
Completion
2020-08-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02885324 on ClinicalTrials.gov